Resistance to β1 integrin inhibition in HER2 amplified cancers is mediated by HER3

被引：0
|
作者：
Park, Catherine C. [1 ]
Amin, Dhara [1 ]
Zhang, Hui [1 ]
Moasser, Mark [1 ]
机构：
[1] UCSF, San Francisco, CA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-5438
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5438
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
    Avisek Majumder
    Manbir Sandhu
    Debarko Banerji
    Veronica Steri
    Adam Olshen
    Mark M. Moasser
    [J]. Scientific Reports, 11
  • [2] The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
    Majumder, Avisek
    Sandhu, Manbir
    Banerji, Debarko
    Steri, Veronica
    Olshen, Adam
    Moasser, Mark M.
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01) : 9091
  • [3] The conditional requirement of HER3 in HER2-amplified breast cancers
    Ruiz-Saenz, Ana
    Dreyer, Courtney
    Steri, Veronica
    Campbell, Marcia
    Gulizia, Nathaniel
    Moasser, Mark
    [J]. MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 94 - 95
  • [4] The role of HER3 in HER2-amplified cancers other than breast cancers
    Majumder, Avisek
    Steri, Veronica
    Salangsang, Fernando
    Moasser, Mark
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [5] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Marcia R. Campbell
    Hui Zhang
    Shabnam Ziaee
    Ana Ruiz-Saenz
    Nathaniel Gulizia
    Julie Oeffinger
    Dhara N. Amin
    Deepika Ahuja
    Mark M. Moasser
    Catherine C. Park
    [J]. Breast Cancer Research and Treatment, 2016, 155 : 431 - 440
  • [6] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Campbell, Marcia R.
    Zhang, Hui
    Ziaee, Shabnam
    Ruiz-Saenz, Ana
    Gulizia, Nathaniel
    Oeffinger, Julie
    Amin, Dhara N.
    Ahuja, Deepika
    Moasser, Mark M.
    Park, Catherine C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 431 - 440
  • [7] HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib
    Wehrenberg-Klee, Eric
    Sinevici, Nicoleta
    Nesti, Sarah
    Kalomeris, Taylor
    Austin, Emily
    Larimer, Benjamin
    Mahmood, Umar
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2021, 23 (06) : 930 - 940
  • [8] HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib
    Eric Wehrenberg-Klee
    Nicoleta Sinevici
    Sarah Nesti
    Taylor Kalomeris
    Emily Austin
    Benjamin Larimer
    Umar Mahmood
    [J]. Molecular Imaging and Biology, 2021, 23 : 930 - 940
  • [9] Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions
    Gerlach, Jan
    Odintsov, Igor
    Schackmann, Ron
    Ladanyi, Marc
    van Bueren, Jeroen Lammerts
    Somwar, Romel
    Geuijen, Cecile
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [10] Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
    Campbell, Marcia R.
    Ruiz-Saenz, Ana
    Peterson, Elliott
    Agnew, Christopher
    Ayaz, Pelin
    Garfinkle, Sam
    Littlefield, Peter
    Steri, Veronica
    Oeffinger, Julie
    Sampang, Maryjo
    Shan, Yibing
    Shaw, David E.
    Jura, Natalia
    Moasser, Mark M.
    [J]. CELL REPORTS, 2022, 38 (05):
12345